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Serum C-reactive protein and leptin as predictors of kidney Identification of factors responsible for the decline in
disease progression in the Modification of Diet in Renal Dis- kidney function characteristic of patients with chronic
ease Study. kidney disease (CKD) is an ongoing area of interest. The
Background. In vitro and in vivo data suggest that markers
Modification of Diet in Renal Disease (MDRD) studyof inflammation and nutritional status may be risk factors for
investigated risk factors for progression of non-diabeticthe progression of chronic kidney disease.
Methods. We investigated whether higher levels of C-reac- kidney disease and found that the presence of polycystic
tive protein (CRP) and leptin were risk factors for progression kidney disease (PKD), the extent of proteinuria, higher
of chronic kidney disease in the Modification of Diet in Renal mean arterial blood pressure, lower high-density lipopro-
Disease (MDRD) Study. Frozen samples were assayed for high
tein (HDL) cholesterol, lower transferrin, and Africansensitivity C-reactive protein (CRP) or leptin in 804 patients.
American race were all independent predictors of subse-CRP and leptin were then evaluated as risk factors for glomeru-
lar filtration rate (GFR) decline using univariate and multivari- quent decline in the glomerular filtration rate (GFR) [1].
able analyses. Together, however, these factors only accounted for 35%
Results. At baseline, the mean (median) CRP in Study A of the variation in GFR decline. Therefore, other factors
(GFR between 25 and 55 mL/min/1.73 m2) and Study B (GFR
are likely also important. We are particularly interestedbetween 13 and 24 mL/min/1.73 m2) were 0.48 (0.25) and 0.46
in markers of inflammation and nutritional status.(0.20) mg/dL, respectively, while the mean (median) leptin in
Study A and Study B were 15.2 (9.80) and 15.1 (7.80) ng/mL, There are several reasons to suspect that markers of
respectively. Mean follow-up time was 2.2 years. The mean GFR inflammation may be risk factors for progression of
decline was 4.33 and 3.65 mL/min/year in Study A and B, CKD. First, serum transferrin, a negative acute phase re-
respectively. There was no significant association between the
actant, was inversely related to the GFR decline in therate of GFR decline with the level of CRP or leptin in multivari-
MDRD Study [1]. This indirectly suggests that higherable analysis in Study A [0.08 (0.14, 0.30) mL/min/year slower
GFR decline per twofold increase in CRP level; and 0.14 levels of a positive acute phase reactant or a marker of
(0.13, 0.40) mL/min/year slower GFR decline per twofold in- inflammation such as C-reactive protein (CRP) may be
crease in leptin level], or in multivariable analysis in Study B a risk factor for progression of CKD. Second, inflamma-
[0.05 (0.28, 0.18) mL/min/year faster GFR decline per two-
tion is known to play an important role in mediatingfold increase in CRP level; and 0.12 (0.42, 0.19) mL/min/
glomerulosclerosis in animal models [2]. Third, there areyear faster GFR decline per twofold increase in leptin level].
many similarities in the pathogenesis of glomerulosclero-Conclusions. Higher serum levels of CRP and leptin are not
independent risk factors for progression of non-diabetic kidney sis and atherosclerosis [3, 4], and systemic markers of
disease. inflammation such as CRP are risk factors for atheroscle-
rotic events [5, 6]. Furthermore, CRP has been shown
to induce adhesion molecule expression in coronary en-
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dothelial cells [7] and to deposit along the walls of glo-Study, inflammation, nutritional status, hyperleptinemia, glomerulo-
sclerosis. merular capillaries [8], raising the possibility that CRP
may play a more direct pathogenic role in both processes.Received for publication March 2, 2002
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Accepted for publication July 22, 2002 tional status may be related to progression of CKD. For
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nutritional status in addition to being a negative acute Samples were then placed on dry ice, shipped overnight
to the Central Biochemistry Laboratory at the Clevelandphase reactant, and as described above was associated
with a faster GFR decline in the MDRD Study. In other Clinic Foundation, and stored at70C. Frozen samples
were then thawed, split and assayed in duplicate for CRPstudies of patients with kidney disease, levels of leptin
(the product of the ob gene) were elevated, and postu- (N  801) and frozen at 70C, rethawed and assayed
in duplicate for leptin (N  798). CRP was measuredlated to be a cause of anorexia. In the current analysis
we chose to focus on leptin as a risk factor for progression using a particle-enhanced technology on the Dade Beh-
ring BN II nephelometer [13]. The method is based onof chronic kidney disease. It is well appreciated that in-
dividuals with massive obesity have high levels of leptin the use of polystyrene particles coated with monoclonal
antibodies specific to human CRP, which form a complexand are predisposed to focal segmental glomerulosclero-
sis [9]. Therefore, it is reasonable to propose that higher with CRP present in the study samples. The amount of
the scattered light in the nephelometer is directly propor-levels of leptin may in some way contribute to glomerulo-
sclerosis. To investigate this hypothesis further, Wolf tional to the antigen-antibody complex and reflects the
amount of high sensitivity CRP present in the samples.et al demonstrated that leptin induced proliferation of
glomerular endothelial cells and enhanced glomerular The assay calibrator is traceable to the WHO reference
material and the detection limit of the method is 0.01transforming growth factor (TGF)-1 and collagen type
IV mRNA expression in rats [10], while Han et al showed mg/dL. Two quality control samples, one with low and
the other with high concentration of CRP are used tothat leptin stimulated glucose uptake and type I collagen
production in diabetic db/db mesangial cells [11]. monitor the run-to-run precision of the assay. The inter-
run coefficient of variances (CVs) for the low and highTo determine whether markers of inflammation and
hyperleptinemia are risk factors for progression of CKD, quality control samples are typically 3.5% and 3.0%,
respectively.we assayed both CRP and leptin in archived serum sam-
ples obtained at baseline from participants in the MDRD Leptin was measured using a commercially available
radioimmunoassay kit (Linco Research, St. Louis, MO,Study.
USA). The assays used antibodies raised against highly
purified human leptin. The within and between run coef-
METHODS
ficient of variations were 3.4 to 8.3% and 3.6 to 6.2%, re-
MDRD Study patients spectively. The sensitivity of the assay was 0.5 ng/mL [14].
Frozen samples from the MDRD Study cohort alsoThe MDRD Study was a randomized controlled trial
of the effect of dietary protein restriction and strict blood were recently assayed for serum creatinine (N  222)
and compared with samples drawn at the same time butpressure control on the progression of kidney disease
[12]. The trial was conducted from 1988 to 1993. Eligi- assayed during the course of the study. The results of the
analysis showed that less than 5% of the frozen samplesbility criteria for enrollment into the MDRD Study in-
cluded age 18 to 70 years, CKD with serum creatinine had any evidence of dehydration. In the remainder of
the samples (N  212), the mean SD of the differencevalues of 1.4 to 7.0 mg/dL (men) and 1.2 to 7.0 mg/dL
(women). Patients with insulin-requiring diabetes, class in serum creatinine between the initial assay and the
repeat assays of frozen samples was –0.08 0.15 mg/dL,III or IV congestive heart failure, renal artery stenosis,
history of kidney transplantation or frequent hospitaliza- while the correlation between the two sets of values
was 0.99 [15]. Thus, there was no evidence of significanttions were excluded. A total of 840 patients were ran-
domized. Study A consisted of 585 patients with a base- dehydration when performing other measurements using
frozen samples from the MDRD Study.line GFR of 25 to 55 mL/min/1.73 m2 and Study B of
255 patients with a baseline GFR of 13 to 24 mL/min/ Institutional review board approval was obtained for
measurement of frozen samples and for the current study.1.73 m2. Rate of decline in GFR, measured as renal
clearance of 125I-iothalamate, was the primary outcome
Statistical analysisof the study. GFR was measured just before randomiza-
tion, at two and four months after assignment, and every Baseline cross-sectional analyses. Means, standard de-
viations, medians, minimum and maximum values werefour months thereafter.
used to describe the baseline values of CRP and leptin.
Measurement of C-reactive protein and leptin The differences in CRP and leptin levels were evaluated
in men and women, using the Mann-Whitney Test. TheFrozen serum samples from the MDRD Study cohort
were available from 804 patients at baseline (560 in Study differences in CRP levels between those with and those
without coronary disease also were analyzed using theA and 244 in Study B) for measurement of either CRP
or leptin. After blood was drawn, samples were allowed Mann-Whitney Test. Spearman correlations were per-
formed between CRP and other continuous variablesto clot at room temperature for a maximum of two hours,
and subsequently spun down and the serum decanted. known to be associated with CRP in the general popula-
Sarnak et al: Predictors of progressive renal disease2210
Table 1. Baseline characteristics of the study populationation, such as body mass index, percent body fat and age.
Similarly, Spearman correlations were performed be- Study A Study B
N  560 N 244tween leptin and other continuous variables known to be
Age at randomization years 52 51associated with leptin in the general population, such as
Male 61 59CRP, body mass index, percent body fat, and insulin level.
Caucasian 85 86
Analysis of GFR declines (slopes). The methods used Type of kidney disease
Polycystic kidney disease 24 23to obtain covariates for this analysis have been described
Glomerular disease 29 36elsewhere [1]. Initially, 41 baseline covariates (excluding
Other 47 41
CRP and leptin) were evaluated as predictors of progres- GFR at randomization mL/min/1.73 m2 38.7 18.5
Current smokers 23 22sion. In Study A, both the low protein diet and the
Body mass index 27.7 26.0low blood pressure goal resulted in a significantly faster
Percentage body fat 31.0 28.6
decline in GFR during the first four months after ran- Coronary heart disease 9 11
Peripheral vascular disease 4 2domization, but a significantly slower GFR decline there-
History of stroke 1 2after [12]. Therefore, the change in GFR was evaluated
Non-insulin dependent diabetes 5 5
using two-slope models in Study A. Based on these two- GFR slope mL/min/year 4.33b 3.65c
slope models, the overall mean rate of change in GFR Data are presented as mean or %.
GFR  glomerular filtration rate.over three years was assessed by a time-weighted average
a Characteristics of the study population with either a CRP or leptin measure-of the initial and final GFR slope. For Study B, the mean ment; b for Study A, mean GFR slope is calculated over three years
c For Study B, calculation of mean GFR slope required at least seven monthsrate of decline in GFR was constant over time. Thus, the
of follow-upchange in GFR was evaluated using a one-slope model.
In Study A, regression coefficients relating the GFR
slopes to baseline covariates were obtained by applying
restricted maximum likelihood under mixed effect mod- This was done to evaluate whether the effect of CRP
els. In Study B, unweighted least-squares regression anal- may be modified by covariates related to CRP.
yses were applied to the GFR slopes from patients with Similarly, the multivariable regression analysis relat-
at least seven months of GFR follow-up. ing leptin to GFR slope was repeated omitting transferrin
Results from previous covariate analysis showed that because of the concern that inclusion of this variable
higher urine protein excretion, presence of PKD, and may mask the effect of leptin. That is leptin may promote
lower serum transferrin were independent predictors of malnutrition and low serum transferrin may reflect mal-
faster progression in both studies A and B, while African nutrition. In separate models, age, gender, log CRP, body
American race, higher mean arterial pressure and lower mass index, percent body fat and log insulin also were
HDL cholesterol were also independent risk factors in added sequentially to the multivariable model. This was
Study A [1].
done to evaluate whether the effect of leptin may be
In this analysis GFR slopes were first related to CRP
modified by covariates related to leptin.and leptin in separate univariate analyses. Subsequently,
Univariate and multivariable regression analyses wereeach of the regression analyses was repeated after con-
then repeated using quartiles of CRP and leptin in ordertrolling for the six baseline variables, which previously
to search for non-linear relationships where differenceswere found to be independent predictors of GFR decline.
may only be appreciated between the first and fourthAll analyses also controlled for diet and blood pressure
quartiles.group assignments. Variables with heavy positive skew-
Finally, because of the known difference in prevalenceness (including leptin and CRP) were log transformed.
of hyperleptinemia in men and women, we evaluated anTo interpret the regression coefficient relating GFR
interaction between leptin and gender with GFR decline.slope to log transformed predictor variables, the coeffi-
Separate subgroup analyses in men and women also werecients were rescaled to estimate the mean difference in
performed.GFR slope associated with each doubling of the pre-
Testing was two sided and P values less than 0.05 weredictor variable.
considered significant. P values and confidence intervalsThe multivariable regression analysis relating CRP to
were not adjusted for multiple comparisons.GFR slope was then repeated omitting both transferrin
and HDL cholesterol because of the concern that the
effect of CRP may be masked by the inclusion of these RESULTS
variables. That is, both transferrin and HDL cholesterol
Study population of subjects with assays performedare associated with inflammation, and therefore may them-
Mean age at randomization was 52 years (Table 1).selves reflect level of inflammation. In separate models
The population was predominantly Caucasian and60%we also sequentially added age, gender, body mass index
and the presence of diabetes to the multivariable model. of subjects were men. Approximately 24% of the subjects
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Table 2. Baseline levels of C-reactive protein and leptin in Studies A and B
Study A Study B
N Mean SD Median Min Max N Mean SD Median Min Max
C-reactive protein mg/dL 559 0.48 0.62 0.25 0.01 7.37 242 0.46 0.64 0.20 0.01 4.28
Leptin all ng/mL 557 15.2 15.3 9.80 0.50 83.8 241 15.1 17.6 7.80 1.20 96.10
Male 339 9.28 8.91 6.80 0.5 70.4 144 8.4 7.78 5.85 1.20 38.90
Female 218 24.4 18.4 19.2 1.5 83.8 97 25 22.8 15.5 2.10 96.10
Table 3. Association of mean GFR slope (mL/min/year) over three years with selected variables in Study A, and with the same selected
variables for patients with at least 7 months of follow-up in Study B
Study A Study B
Univariate Multivariablea Univariate Multivariablea
RRCb (CI) (P) RRCb (CI) (P) RRCb (CI) (P) RRCb (CI) (P)
CRP mg/dLc 0.12 (0.13, 0.37) (0.35) 0.08 (0.14, 0.30) (0.46) 0.001 (0.25, 0.25) (0.99) 0.05 (0.28, 0.18) (0.68)
Leptin ng/mLc 0.32 (0.02, 0.62) (0.04) 0.14 (0.13, 0.40) (0.31) 0.02 (0.34, 0.30) (0.90) 0.117 (0.42, 0.19) (0.46)
Abbreviations are: RRC, rescaled regression coefficient; CRP, C-reactive protein; CI, 95% confidence interval.
a Adjusting for 6 baseline covariates: polycystic kidney disease, extent of proteinuria, mean arterial pressure, high-density lipoprotein cholesterol, serum transferrin
level, African American race as well as randomization to different blood pressure and protein intake
b Expressed as doubling of the predictor for log-transformed variables
c Log transformed
had PKD as the cause of their kidney disease in both (r  0.30, P  0.001), body mass index (r  0.45, P 
0.001) percent body fat (r  0.41, P  0.001), and ageStudy A and B, while 29 and 36% had glomerular disease
as the cause of their kidney disease in Study A and (0.31, P  0.001). CRP was not significantly correlated
with GFR in univariate analysis. Leptin was directly cor-B, respectively. Approximately 10% of subjects had a
history of coronary artery disease while only a small related with body mass index (r  0.39, P  0.001),
percent body fat (r 0.64, P 0.001), and serum insulinpercentage had a history of non-insulin dependent diabe-
tes, peripheral vascular disease or stroke. Mean GFR at level (r  0.32, P  0.001). Leptin was not significantly
correlated with GFR in univariate analysis but wasrandomization in Study A and Study B were 38.7 and
18.5 mL/min/1.73 m2, respectively. Mean follow-up time weakly negatively correlated with GFR after partial ad-
justment for body mass index, percent body fat and gen-was 2.2 years, and mean GFR slope decline was 4.33
and 3.65 mL/min/year in Study A and B, respectively. der (r  0.11, P  0.003). The explanation for the
difference between the univariate and partial adjustmentThe baseline characteristics of the subjects who did not
have CRP or leptin measured (N 36) were not statisti- analysis is the confounding effect of decreased body mass
index and decreased percent body fat as GFR declinescally different from those who had these analytes mea-
sured (N  804) (data not shown). (Table 1).
Relationship between baseline CRP and progressionBaseline levels of CRP and leptin
of kidney diseaseThe baseline levels of CRP, leptin and insulin in Study
A and B are shown in Table 2. Mean (median) CRP C-reactive protein at baseline was not significantly as-
sociated with rate of decline in kidney function in univar-level (mg/dL) in the entire cohort, Study A, and Study
B were 0.47 (0.24), 0.48 (0.25), and 0.46 (0.20) mg/dL iate or multivariable analysis in Study A or B (Table 3).
In neither Study A (P 0.662) nor Study B (P 0.739)respectively. Median CRP values were higher in women
than men (0.29 vs. 0.22 mg/dL, P  0.047 by Mann- was CRP associated with GFR decline in multivariable
analysis after omitting serum transferrin and HDL cho-Whitney) and in those with a history of coronary artery
disease compared to those without coronary artery dis- lesterol from the regression analysis. Similarly, if age, gen-
der, body mass index and the presence of diabetes wereease (0.42 vs. 0.22 mg/dL, P  0.001 by Mann-Whitney).
Mean (median) leptin (ng/mL) in the entire cohort, sequentially added to the model, there was no significant
relationship between CRP and GFR decline in eitherStudy A, and Study B were 15.2 (9.10), 15.2 (9.80), and
15.1 (7.80), respectively. Median leptin levels were Study A or B at any time during building of the model.
There was also no consistent linear or non-linear rela-higher in women than men (18.3 vs. 6.4 ng/mL, P 0.001
by Mann-Whitney) in the entire cohort. tionship between baseline CRP and slope in either Study
A or B in univariate or multivariable analysis (Fig. 1).C-reactive protein was directly correlated with leptin
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Fig. 2. (A) Association of mean GFR slope over three years withFig. 1. (A) Association of the mean glomerular filtration rate (GFR)
baseline leptin in Study A. The 25th, 50th and 75th percentiles for leptinslope over three years with baseline C-reactive protein (CRP) in Study
were 5.1, 9.8 and 18.75 ng/mL, respectively. (B) Association of meanA. The 25th, 50th and 75th percentiles for C-reactive protein were 0.12,
GFR slope with baseline leptin in Study B. The 25th, 50th and 75th0.25 and 0.65 mg/dL, respectively. (B) Association of mean GFR slope
percentiles for leptin were 4.1, 7.80 and 18.9 ng/mL, respectively.with baseline CRP in Study B. The 25th, 50th and 75th percentiles for
C-reactive protein were 0.09, 0.2 and 0.54 mg/dL, respectively.
cline in either Study A or B at any time during building
Relationship between baseline leptin and progression of the model.
of kidney disease There was also no consistent linear or non-linear rela-
tionship between baseline leptin and slope in either StudyIn univariate analysis, higher levels of leptin were asso-
A or B in univariate or multivariable analysis (Fig. 2).ciated with a slower rate of progression (a positive re-
However, there was a significant interaction betweenscaled regression coefficient indicated a slower rate of
gender and leptin with GFR decline in Study B (P progression) in Study A, while in multivariable analysis
0.026) but not Study A (P 0.399). The subgroup analy-higher levels of leptin were not significantly associated
sis was consistent with the interaction. That is, leptinwith the rate of decline in kidney function in either Study
was significantly associated with GFR decline in femalesA or B (Table 3).
in Study B (rescaled regression coefficient 0.50, 95%In neither Study A (P  0.18) nor Study B (P 
CI 0.06 to 0.93, P  0.002) in multivariable analysis.0.785) was serum leptin associated with GFR decline in
The same was not seen in men in Study B (P  0.616)multivariable analysis after omitting serum transferrin
or in men (P  0.443) or women (P  0.985) in Studyfrom the regression analysis. Similarly, if age, gender,
A, however. The significant association between leptinlog CRP, body mass index, percent body fat and log
and GFR decline in females in Study B persisted despiteinsulin were sequentially added to the model, there was
no significant relationship between leptin and GFR de- an additional adjustment for body mass index.
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Interpretation of the rescaled regression coefficients multiple comparisons without a formal adjustment and,
therefore, a single spurious result due to a Type I errorand the 95% confidence intervals in Study A and
Study B using an example may not be unexpected. Third, in the studies of obesity
associated glomerulosclerosis there has been no obviousIn Study A, the rescaled regression coefficient for CRP
predilection for females being affected [19].was 0.08 mL/min/year per doubling of CRP (Table 3).
It is important to note that the lack of associationThis indicates that for every twofold higher baseline CRP
between serum levels of CRP and leptin (in the entire(for example, a CRP level of 0.4 vs. 0.2 mg/dL), the
cohort) with progression does not necessarily imply aregression model estimated a 0.08 mL/min/year slower
lack of causation between inflammation and leptin withmean rate of decline in GFR. The confidence interval
progression of human kidney disease. For example, se-ranged from a 0.14 mL/min/year faster decline to a 0.30
rum levels of CRP may not accurately reflect the underly-mL/min/yr slower decline. The lower endpoint of 0.14
ing inflammatory milieu in the kidney and therefore maymL/min/year indicated it was unlikely that a doubling of
be an insufficient marker of the extent of inflammationCRP would lead to an increase in the mean rate of GFR
in the kidney. It is tempting to hypothesize that moredecline greater than 0.14 mL/min/year (less than 4% of
local measures of inflammation may be more predictivethe mean slope of 4.33 mL/min/year).
of CKD progression [20]. Indeed, there are limited, al-
though inconsistent, data suggesting that inflammatory
DISCUSSION urinary cytokines such as interleukin-6 [21] or TGF-
[22] may be predictive of CKD progression. Similarly,In vivo and in vitro data suggest that inflammation is
an important mediator in promoting glomerulosclerosis. it also is possible that tissue levels of leptin may be as-
sociated with GFR decline. That is, serum levels of leptinGlomerulosclerosis involves an influx of monocytes, pro-
duction of lipid laden tissue macrophages, proliferation may not be sensitive enough to detect the association be-
tween tissue levels of leptin and progression of kidneyof contractile cells, expansion of the extracellular matrix
and ultimately the production of types I and IV collagen disease.
Much of the data relating leptin to fibrogenesis andand fibronectin [2–4, 16]. The presence of inflammatory
cytokines such as interleukin-1, TGF-, and platelet- glomerulosclerosis has been obtained from diabetic ani-
mal models [11]. Hyperleptinemia occurs more frequentlyderived growth factor all contribute to this process.
In vivo and in vitro data also suggest that leptin may in patients with insulin resistance [23] and may play a
more pathogenic role in diabetic patients who are at acontribute to glomerulosclerosis [10, 11]. Leptin induces
the production of TGF-1 in glomerular endothelial cells particularly increased risk for progression of CKD. That
is, hyperleptinemia may act in concert with other cyto-[10] and has been shown to enhance glucose uptake and
to up-regulate TGF- type II receptor expression [11]. kines present in diabetic nephropathy to promote glo-
merulosclerosis. The MDRD Study cohort was predomi-The latter results in an increase in type I collagen deposi-
tion in the mesangium. nantly a non-diabetic population; therefore, we are unable
to address the hypothesis whether leptin is a risk factorBased on these data we hypothesized that CRP, a
marker of systemic inflammation, and hyperleptinemia for progression of CKD in an exclusively diabetic popu-
lation.may be risk factors for progression of chronic kidney dis-
ease. Our results did not show strong or consistent evi- Finally, with regard to both leptin (in the entire cohort)
and CRP, we acknowledge that we cannot be sure thatdence of an association of serum levels of CRP or leptin
with the progression of kidney disease in the MDRD a small relationship between the primary variables with
GFR slope was not overlooked. This seems unlikely, how-cohort. We did observe, however, that leptin was associ-
ated with progression of kidney disease in females in ever, in that our rescaled regression coefficient for CRP
and leptin are positive in Study A (that is, higher levelsStudy B.
A difference between the effect of leptin in men and are associated with a slower rate of progression), and
the standardized 95% confidence intervals are relativelywomen was not a primary hypothesis of ours; however,
it deserves additional consideration and should be inves- narrow (in both Study A and B) and appear within the
range of normal age-associated decline in GFR of 1 mL/tigated in future studies. Estrogen can promote glomeru-
losclerosis in certain animal models [17, 18] and one min/year. Therefore, if CRP or leptin has any effect on
subsequent GFR decline, the effect size is probablycould propose that leptin in combination with estrogen
(or other female hormones) may be associated with pro- small. Furthermore, it is important to note that the mean
decline in GFR slope was 3.65 to 4.33 mL/min/yeargression of kidney disease. However, caution should be
exercised in interpreting this result for three reasons. in the MDRD Study (Table 1); hence, the maximum ef-
fect of any of these primary variables would be smallFirst, no similar trend was seen in Study A in spite of
its larger sample size and in spite of similar levels of leptin compared with the average decline in GFR per year.
The major potential limitation of our analyses is thein females in Study A (Table 2). Second, we performed
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fact that frozen samples were used. In theory, the use MDRD Study participants with PKD, the distribution
of frozen samples can result in incorrect values due to of renal diagnoses is similar to ESRD patients due to
either sample breakdown or hemoconcentration due to non-diabetic kidney disease [38].
dehydration of sample. However, several lines of indirect In conclusion, CRP and leptin do not appear to be
support exist for the accuracy of our measurements. First, major risk factors for kidney disease progression in a
prior studies have suggested both CRP and leptin are predominantly non-diabetic cohort. These relationships
stable after multiple freeze and thaw cycles [14, 24–26], need to be confirmed in additional studies.
and that CRP and leptin are believed to be stable and
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